Savvy Pharma and Mabwell are pleased to announce the officially signed partnership agreement to commercialize their first biosimilars in the region.
Savvy Pharma will register and commercialize selected Biosimilars which are developed and manufactured by Mabwell to address a critical healthcare void in the treatment of both bone diseases and oncology.

This partnership reflects our shared commitment to innovation, quality, and the pursuit of excellence in improving the quality of life for people by harnessing science and technology to provide highly reliable medicine.

By combining our strengths with those of Mabwell, we aim to achieve sustainable innovation that contributes to a healthier and more equitable future and we look forward to the positive impact this collaboration will bring to our company, our partners, and most importantly, the patients who depend on our products.


#savvypharma #jordan #MENA #partnership #biopharma